Skip to main
CMRX
CMRX logo

Chimerix (CMRX) Stock Forecast & Price Target

Chimerix (CMRX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 23%
Hold 41%
Sell 5%
Strong Sell 0%

Bulls say

Chimerix Inc. recently received FDA acceptance for its New Drug Application (NDA) seeking accelerated approval for dordaviprone, a treatment for recurrent H3 K27M-mutant diffuse glioma, highlighting the company’s potential for near-term commercialization opportunities. Additionally, Chimerix has announced a definitive agreement with Jazz Pharmaceuticals for acquisition at $8.55 per share, amounting to a total value of approximately $935 million, which signifies a substantial premium and reflects market confidence in Chimerix's strategic direction. Furthermore, the amended loan agreement for up to $30 million positions the company to enhance its financial stability as it advances its product pipeline.

Bears say

Chimerix Inc. has been downgraded due to the recently announced acquisition, prompting a revision in its rating and a price target adjustment to $8.55, reflecting the acquisition price. This downgrade may indicate concerns over the company's stability and growth potential following the acquisition, suggesting potential challenges in its financial outlook. Furthermore, the reliance on revenue from non-refundable upfront fees, royalties, and milestone payments may leave the company vulnerable to fluctuations in cash flow and profitability.

Chimerix (CMRX) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 23% recommend Buy, 41% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Chimerix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Chimerix (CMRX) Forecast

Analysts have given Chimerix (CMRX) a Buy based on their latest research and market trends.

According to 22 analysts, Chimerix (CMRX) has a Buy consensus rating as of Aug 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Chimerix (CMRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.